“Program Description

This expert-led webinar will explore the state of HCV in the United States, testing and treatment recommendations, key barriers to HCV treatment access and their impacts, how payers benefit from expanding HCV treatment access, treatment considerations for today's complex HCV population, and a treatment option that addresses many of the needs of today's patient population.

Nearly a decade after the development of direct-acting antiviral treatments that can cure HCV in more than 95% of people infected, only a small fraction of the 2.5 million people with chronic HCV in the United States have received treatment, and tens of thousands still die from the disease every year. This expert-led webinar will highlight:

• How many people in the United States have HCV and what percentage are diagnosed and treated

• Which patients are currently most likely to be infected with HCV

• HCV screening and treatment recommendations from major medical organizations

• Major barriers to HCV treatment and which patients are most impacted by them

• Benefits for payers of expanding HCV treatment access

• Important treatment considerations for today's complex chronic HCV patient population, including common comorbidities, concomitant medications, and lifestyle factors

• A treatment option for HCV that addresses many of the needs of today's patient population

Learning Objectives

The objectives of this presentation are to:

• Illustrate the burden of HCV in the United States and key barriers to HCV treatment access

• Present data on the potential cost savings generated by treating HCV

• Highlight important treatment considerations for today's complex HCV patient population and present information about a treatment option for chronic HCV and how it addresses the needs of today's patient population”